Fairvalue-Calculator Fairvalue-Calculator
EN DE

Definium Therapeutics, Inc (DFTX) Fair Value & Analysis

Healthcare · US · Market cap $2.4B

Price$36.18
Fair Value$13.71
Upside-62.1%
Quality95/100
Evidence: Low Range $10.28 – $17.14

Fair value as of: Jun 24, 2026

Analysis

Definium Therapeutics, Inc (DFTX) currently trades at $36.18, while our model-based Fair Value estimate is $13.71 — implying the stock looks roughly 62.1% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. is headquartered in New York, New York.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -84% Regeneron Pharmaceuticals, Inc (REGN) +109% UCB SA (UCB) -28% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -64%

Frequently asked questions

Is Definium Therapeutics, Inc (DFTX) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $13.71 versus a price of $36.18 — about −62% (overvalued). Model-based estimate, not financial advice.
What is the fair value of DFTX?
Our 21-model fair value for Definium Therapeutics, Inc is $13.71 (as of Jun 24, 2026), built from audited fundamentals. The current price is $36.18.
What is the quality score of DFTX?
Definium Therapeutics, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.